Biohealth Innovation
As the first buildings at Port Covington begin to rise, the project’s developers have a vision for the mini-city sprouting on a South Baltimore peninsula as the nation’s next big biotech hub.
The waterfront neighborhood of apartments, offices, stores and parks now under construction could rival life sciences cores such as Cambridge, Massachusetts, and Mission Bay in San Francisco, members of the development team say.
BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary that translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking two experienced life science professionals with product development and investment experience to join the BHI team to serve as a part-time Entrepreneurs-in-Residence (EIR) at the National Institutes of Health (NIH).
These positions will report to and work closely with our lead at the NIH Small business Education and Entrepreneurial Development (SEED) Office to support academic and small business innovators in their efforts to validate the potential health impacts of promising scientific discoveries and advance them into healthcare products that improve patient care and enhance health.
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Sue Carr, RPh, President and Founder, CarrTech, LLC.
Sue Carr RPh is President and Founder of CarrTech LLC, a medical device company. CarrTech has developed, patented, and prototyped an all-in-one package one needle filter device to increase safety and compliance while reducing time and waste. Sue has over 30 years of experience in the pharmaceutical industry in retail management and clinical hospital pharmacy, specializing in ICU, ER, Oncology, and NICU.
GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2021. In our inaugural year for these awards, we wanted to bring forth and recognize not only the most experienced and talented investors in healthcare but also those that help advance innovation across the sector. Over 750 investors were considered. Whether in healthcare software, healthcare services, medical technologies, biotechnology, the connected patient experience, or other areas, the accomplished individuals who were ultimately selected have demonstrated a deep commitment to healthcare and as a result have succeeded both from a business standpoint as well as in having significant societal impact.
Image: https://growthcapadvisory.com
As biopharma companies continue to cope with the COVID-19 pandemic and position themselves for recovery, digital and analytics can be a powerful tool in manufacturing and operations. It can drive the next wave of business optimization by transforming operational performance, shortening time to market, improving quality and yield, reducing supply chain volatility, and accelerating technology transfers.
There is no denying that the venture capital industry is red hot right now. When you open up websites like Forbes, Techcrunch, and Business Insider, it is almost impossible to miss all of the news about the biggest deals in Silicon Valley being made by these firms.
Anew partnership led by University of Maryland researchers has entered a cooperative agreement with the U.S. Army Research Laboratory (ARL) that could provide up to $68 million to drive advances in artificial intelligence and autonomy.
An interdisciplinary research team from UMD and the University of Maryland, Baltimore County (UMBC) aims to create a new generation of technologies and devices—from wearables to unmanned aircraft—able to intelligently work alone or in teams with other devices, as well as safely and effectively collaborate with their human operators in different environments.
Saw a familiar face on ABC News 7 tonight! Congrats to the American Gene Technologies International Inc. team on the first patient dosing in the #HIVCure Ph 1 trial. 🧬🚀☝🏼
Five finalists have been named in the prestigious annual “Make Your Medical Device Pitch for Kids!” competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in electrophysiology devices that treat congenital heart disease (CHD) and arrhythmias in pediatric patients, these five finalists now have access to a pediatric accelerator program led by MedTech Innovator and will compete for a share of $150,000 in grant funding from the U.S. Food and Drug Administration (FDA) in the final virtual pitch event in September 2021. The pediatric pitch event is part of the 9th Annual Symposium on Pediatric Device Innovation, co-located with the MedTech Conference, powered by AdvaMed.
HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)– QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.
The bio economy is booming across the U.S., and not just in Boston or San Francisco. States are witnessing a resurgence of life science research and technology commercialization. There is a boom of advanced manufacturing as construction of wet lab space takes place in research parks and tech incubators creating new space to attract and grow bio tech companies. Innovative federal and state policies are aiding in the emergence of bio tech entrepreneurs.
As one of the most important global bio-health conventions, BIO KOREA 2021 International Convention has garnered great attention from home and abroad. To facilitate the discussion on the future bio-health industry in the ‘COVID-19 era’, the BIO KOREA 2021 to be held on June 9 to 21 will evolve around the theme of “New Normal: Breaking Barriers with Bio Innovation”.
LEIDEN, the Netherlands, May 27, 2021 / B3C newswire / -- MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. In contrast to other Organ-on-a-Chip platforms, the MIMETAS OrganoPlate® technology offers the scalability and the throughput needed for drug discovery studies.
A study led by researchers from the Institute Cajal of Spanish Research Council (CSIC) in Madrid, Spain in collaboration with the Bioengineering Department of George Mason University in Virginia, U.S. has updated one of the world's largest databases on neuronal types, Hippocampome.org.
The study, which is published in the journal PLOS Biology, represents the most comprehensive mapping performed to date between neural activity recoded in vivo and identified neuron types. This major breakthrough may enable biologically meaningful computer modeling of the full neuronal circuit of the hippocampus, a region of the brain involved in memory function.
Image: https://medicalxpress.com
Dr. Laurie E. Locascio, Vice President for Research at both the University of Maryland College Park and Baltimore, Visits BioTalk to Discuss Her Career, Tech Transfer, and the Two Institutions Working Together
Listen now on Apple https://apple.co/3oZKsNP, Google https://bit.ly/3vpYr1T, Spotify https://spoti.fi/2QZm3vd, and TuneIn https://bit.ly/2RQqs40.
Laurie E. Locascio, Ph.D., is the Vice President for Research at the University of Maryland, College Park and the University of Maryland, Baltimore.
Montgomery County (MOCO), Maryland, sits at the epicenter of biopharma growth, investment, and innovation that makes the BioHealth Capital Region (BHCR) one of the top bio clusters in the world. The past 15 or so months has seen the region’s biohealth momentum accelerate significantly, spurred on by the race to develop a SARS-CoV-2 vaccine, expansion in the cell and gene therapy sector, as well as increased activity around advanced biomanufacturing, among other positive indicators.
Image: https://biobuzz.io
FREDERICK, Md.--(BUSINESS WIRE)--BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first time BFI-751 has been administered to humans, as authorized by the Ethics Committees in both Australia and New Zealand.
A local biotech has secured millions of dollars in new investments to take its RNA therapies for drug-resistant cancers to the clinic.
Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.
Gaithersburg, MD. (May ____ 2021) miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.
The startup is developing therapeutics for drug-resistant cancers — and applying its technology to other arenas, including Covid-19.
Image: MiRecule CEO Anthony Saleh, shown here in 2018, views protein molecules in a silver stained gel. JOANNE S. LAWTON
Are you and early stage company with innovative biohealth technology? Have you considered non-dilutive funding to advance your technology? Learn more about whether or not federal or state non-dilutive funding makes sense for you. Discuss potential strategies for success. Sign up for a free 1:1 advice and feedback regarding non-dilutive funding strategy and applications with BHI staff who have helped companies secured SBIR, STTR and other awards—at twice the national average win rate.
Are you and early stage company with innovative biohealth technology? Have you considered non-dilutive funding to advance your technology? Learn more about whether or not federal or state non-dilutive funding makes sense for you. Discuss potential strategies for success. Sign up for a free 1:1 advice and feedback regarding non-dilutive funding strategy and applications with BHI staff who have helped companies secured SBIR, STTR and other awards—at twice the national average win rate.
RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. RoosterGEM, abbreviated for Rooster Genetic Engineering Medium, complements RoosterBio’s hMSC cell engineering system to offer a new and streamlined path for discovery, preclinical, and applied product development research - faster than ever before.
BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking an experienced life science professional with venture investment experience to join the BHI EIR team and serve as a part time Entrepreneur-in- Residence (EIR) at the National Institutes of Health (NIH) for the National Institute on Aging (NIA).
This position will report to and work closely with our lead at the NIH Office of the Director, Office of Extramural Research and specifically support the portfolio of companies funded by NIA’s ~$130M annual investment in small businesses focused on Alzheimer’s disease & related dementias, disorders of aging and supportive technologies for senior living and care providers.
BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking an experienced life science professional with venture investment experience to join the BHI EIR team and serve as a part time Entrepreneur-in- Residence (EIR) at the National Institutes of Health (NIH) for the National Institute on Aging (NIA).
This position will report to and work closely with our lead at the NIH Office of the Director, Office of Extramural Research and specifically support the portfolio of companies funded by NIA’s ~$130M annual investment in small businesses focused on Alzheimer’s disease & related dementias, disorders of aging and supportive technologies for senior living and care providers.
Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback
For questions/more information, contact BHI.
Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback
For questions/more information, contact BHI.
Blu Venture Investors, a Vienna, VA-based venture capital firm supporting the cybersecurity ecosystem in the Mid-Atlantic region and beyond, launched a $25M fund.
The BVI Cyber Fund is targeted at Series A growth companies in cybersecurity.
Blu Ventures has and will continue to invest in forward-looking cybersecurity technologies within core areas that include Endpoint Detection & Response, Data Storage; Web & Cloud; Messaging; Network; Industrial & Internet of Things (IoT); Threat Intel; Mobile; Fraud Protection & Transaction; Risk, Compliance & Training; Specialized Threat Analysis & Protection and Security Ops & Incident Response.
Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease (MVD). MVD is caused by either of two marburgviruses, Marburg virus and Ravn virus, and has reemerged several times since it was initially described in 1967. IBT-T03H, discovered in collaboration with the University of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.
May 20, 2021 (Washington, D.C.)- Connected DMV held its ninth and final COVID-19 Strategic Renewal Task Force meeting, where they announced the formation of the DMV Regional Congress to continue the Task Force’s mission of advancing strategic initiatives to promote economic renewal and social equity in the region. Washington, D.C. Mayor Muriel Bowser also addressed the Task Force, where she gave an update on the District’s reopening plans. She also thanked the cross-sector regional nonprofit for its work in bringing together all of the region’s stakeholders for the shared purpose of creating a more economically vibrant and equitable future for all in Greater Washington on behalf of the District and Maryland and Virginia Governors Larry Hogan and Ralph Northam.
Image: https://www.connecteddmv.org
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach® Anti-SARS-CoV-2 Total Test.
The authorization means QIAGEN can start making its portable antibody testing device available to health-care professionals in the U.S. Each antibody test takes only about 10 minutes to identify whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection. Individual test results are read on a digital eHub device that can process up to 32 tests per hour – and will eventually also run the antigen test.
FREDERICK, Md.--(BUSINESS WIRE)--Today, the Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners for its annual Industry Awards Celebration. The event recognizes the leaders and innovators in the life sciences and technology communities from Maryland and the Mid-Atlantic Region. Winners were announced at the virtual celebration event today at 4pm ET.
“We are proud to celebrate and honor these companies and individuals in the life sciences and technology industries who are doing important work to improve lives,” said MTC CEO Marty Rosendale. “The work done by these industries is necessary now more than ever to help advance the state and the country. Each year, the Industry Awards Celebration brings out the best that the region has to offer, and 2021 was no exception.”
The COVID-19 pandemic has had a substantial impact on global health and highlighted the importance of international cooperation to effectively combat SARS-CoV-2. Since the discovery and publication of the virus’s genome in January 2020, scientists have rushed to develop vaccines, therapeutics and diagnostics on an unprecedented timescale. To date there are 80 vaccines in clinical trials and 70 more in clinical development, setting the stage for some of the fastest vaccine development and testing in modern history1. The vaccine technology platforms used by the most promising vaccine candidates range from viral vector–based and protein-based technologies to mRNA and lipid nanoparticle technology. Despite these impressive scientific achievements, barriers such as the vaccine cold chain and multiple forms of intellectual property (IP) protection stand in the way of equitable access and fair allocation.
Image: https://www.nature.com
The April jobs report, released by the Bureau of Labor Statistics on May 7, generated considerable attention due to the 266,000 jobs added being far less than anticipated. Contributing to this topline number are quite a few trends moving in different directions, including a severe decline in automotive manufacturing employment — likely driven by the global semiconductor shortage — increasing restaurant and R&D employment, and declines in part-time work. Ultimately, the April employment data suggest a far more complex portrait of the economy than what is being covered in many sources.
The universal impact of the COVID-19 pandemic has forever changed our understanding of the lives we knew both collectively and personally. No one is immune to the effects of an “enemy” that we cannot see and at times cannot comprehend.
It would be safe to say that feelings of uncertainty and uneasiness are a normal part of our daily lives over the past year. Regaining a sense of control and the promise of returning to some semblance of safety and normalcy is a priority.